



Terapet SA secures over CHF 2,3 million to bring its first product to market and to accelerate development of new nuclear imaging products.

Geneva February 17th, 2023 Terapet, a privately held Swiss MedTech company developing next generation imaging technology, is pleased to announce the new investment of CHF 2,3 million as the first closing of the Pre-Series A investment round. This funding supports the commercialization of Terapet's first product, [Qualyscan](#) and the development of new nuclear imaging products.

The funding round was co-led by EFI Lake Geneva Ventures and Nina Capital with support of all the existing shareholders including Fongit, Venturekick and the founders.

Terapet's novel technology, developed in collaboration with leading research institutes CERN and Politecnico di Milano, has the potential to make nuclear medicine imaging more accessible for every patient in the future.

The first product, [Qualyscan](#) is a novel proton therapy quality assurance device which, for the first time, will provide a way of assessing the real-time dose distribution. The device will be validated together with clinical partners at the Karolinska Institute and Skandion Clinic. In the coming years, the same technology will enable medical doctors to monitor the delivered dose inside the patients during cancer treatment: in-vivo, non-invasively, in 3D and real-time.

"With our solution, we will eliminate one of the biggest obstacles to particle therapy: ensuring that every patient receives the right dose, every time," says Dr. Christina Vallgren, CEO of Terapet. "We look forward to showcasing our first product to the particle therapy community at this year's [PTCOG](#) in Madrid. This funding is essential to support the marketing and sales campaign for [Qualyscan](#)."

Terapet also welcomes new members to its Board of Directors: Giovanni Leo from EFI Lake Geneva Ventures and Sebastian Anastassiou from Nina Capital.

"I am thrilled to join the board of Terapet and contribute to the development of the next generation of nuclear imaging products. As a MedTech professional, I have long been passionate about the potential of medical imaging to improve patient outcomes and I believe that Terapet is uniquely positioned to lead the way in this space. I look forward to working alongside the talented team at Terapet to help drive innovation, enhance our technology, and ultimately, make a meaningful impact on the healthcare industry." – says Giovanni Leo, partner of EFI Lake Geneva Ventures.

Principal from Nina Capital, Sebastian Anastassiou who will also join the new board, said, "I am excited to continue supporting Terapet towards realizing their vision of drastically improving patient outcomes by developing the future of nuclear imaging. With solid technology foundations out of CERN and a stellar team, we have all the right ingredients to work together towards true healthcare impact."

Founders:

Dr. Christina Vallgren
CEO

christina.vallgren@terapet.ch

Dr. Marcus Palm
CTO

marcus.palm@terapet.ch

Prof. Raymond Miralbell
CSO

Raymond.Miralbell@quironsalud.es

Investors & collaborators

About Efficient Frontier Investing

[EFI Lake Geneva Ventures](#) is Geneva-based seed and early-stage investment strategy with the mission to foster innovation in Technology, Life Sciences and MedTech. In partnership with the Swiss network of incubators and with close proximity to universities and research centers, it benefits from early access to the best innovations and cherry-pick the most attractive and innovative opportunities in the market.

About Nina Capital

[Nina Capital](#) is a European venture capital firm focused on early-stage investments in health technology companies. It is inspired by a vision for the future in which data derived through computing, IoT and sensor technologies deliver meaningful insight for improving health and the provision of care.

About FONGIT

The “Fondation Genevoise pour l’Innovation Technologique” – [FONGIT](#), founded in 1991, is Switzerland’s premier innovation incubator supporting innovative tech ventures in Geneva. Fongit is a private, non-profit foundation, whose mission is to transform technology into social & economic value in the Geneva region. Terapet is a Fongit supported company.

About CERN

[CERN](#), the European Laboratory for Particle Physics, is one of the world's largest and most respected centres for scientific research. It provides a unique range of accelerator, detector and computing facilities that enable world-class research in fundamental physics.

Two of the co-founders are former CERN physicists with more than 12 years’ experience from CERN. [Terapet and CERN](#) collaborate via an Innovation Project funded by Innosuisse, in the development of Terapet’s first full-scale prototype.

About Karolinska Institute and Skandion Clinic

The Nobel Prize-awarding [Karolinska Institute](#) in Stockholm, founded in 1810, is Sweden’s only university with a core focus on biomedical sciences and ranks as one of the world’s leading medical universities.

The [Skandion Clinic](#) in Uppsala, Sweden, is the first clinic in the Nordic region to offer proton radiation treatments and opened in 2015, currently treating ~300 patients every year.

[Terapet collaborates with Karolinska and the Skandion Clinic](#) through the Eurostars project co-financed by Innosuisse, the Swiss Innovation Agency and Vinnova, the Swedish Innovation Agency in 2021.

About Politecnico di Milano

Politecnico di Milano is one of the best scientific-technological universities in the world according to the prestigious QS World University Rankings. [Terapet and Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria](#) are in a three years’ Research and Development partnership.